Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: A review

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 4, 2009, Pages 415-422

  Neuhut, Rachel ^a,e   Lindenmayer, Jean Pierre ^a,b,c   Silva, Raul ^a,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MANHATTAN PSYCHIATRIC CENTER   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CLOTIAPINE; CLOZAPINE; DANTROLENE; HALOPERIDOL; LITHIUM; LORAZEPAM; METHYLPHENIDATE; OLANZAPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ACUTE PSYCHOSIS; ADJUVANT THERAPY; ADOLESCENT; ADULT; AKATHISIA; ARTICLE; AUTISM; AUTOMATION; BIPOLAR DISORDER; BLOOD PRESSURE; CHILD; CHILD PSYCHIATRY; CLINICAL ARTICLE; CONSCIOUSNESS LEVEL; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIAPHORESIS; DRUG FATALITY; DRUG WITHDRAWAL; EEG ABNORMALITY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; HEART RATE; HUMAN; LEUKOCYTE COUNT; MALE; MENTAL HEALTH; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOSIS; RIGIDITY; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHOOL CHILD; SIDE EFFECT; STATISTICS; TACHYCARDIA; TACHYPNEA; TREATMENT DURATION;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CHILD; HUMANS; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; TACHYCARDIA;

EID: 69549114805     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0130     Document Type: Article

References (30)

1. Aboraya A, Schumacher J, Abdalla E, LePage J, McGhee M, Butcher D, Griffin H, Shahda M: Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. W V Med J 98:63-65, 2002.
2. Abu-Kishk I, Toledano M, Reis A, Daniel D, Berkovitch M: Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. J Toxicol Clin Toxicol 42:921, 2004. (Pubitemid 39426220)
3. Addonizio G., Susman V, Roth S: Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biol Psychiatry 22:1004-1020, 1987. (Pubitemid 17095324)
4. th edition (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
5. Berry N, Pradhan S, Sagar R, Gupta SK: Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy 23:255-259, 2003. (Pubitemid 36197467)
6. Bonwick RJ, Hopwood MJ, Morris PL: Neuroleptic malignant syndrome and risperidone: A case report. Aust N Z J Psychiatry 30:419-421, 1996. (Pubitemid 26253954)
7. Brown CS, Markowitz JS, Moore TR, Parker NG: Atypical anti-psychotics: Part II: Adverse effects, drug interactions, and costs. Ann Pharmacother 33:210-217, 1999. (Pubitemid 29109684)
8. Caroff SN, Mann SC, Campbell ED: Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 30:314-321, 2000.
9. Chungh DS, Kim BN, Cho SC: Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 19:422-425, 2005. (Pubitemid 41003140)
10. Croarkin PE, Emslie GJ, Mayes TL: Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: A review of published cases. J Clin Psychiatry 69:1157-1165, 2008.
11. Delay J, Deniker P: Drug-induced extrapyramidal syndromes. Handbook of Clinical Neurology. Diseases of the Basal Ganglia, Volume 6, Vinken PJ, Bruyn GW, eds. New York: Elsevier/North Holland, pp 248-266, 1968.
12. Farver DK: Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Safety 2:21-35, 2003.
13. Ghaziuddin N, Alkhouri I, Champine D, Quinlan P, Fluent T, Ghaziuddin M: ECT treatment of malignant catatonia/NMS in an adolescent: A useful lesson in delayed diagnosis and treatment. J ECT 18:95-98, 2002. (Pubitemid 35012000)
14. Hammerman S, Lam C, Caroff SN: Neuroleptic malignant syndrome and aripiprazole. J Am Acad Child Adolesc Psychiatry 45:639-641, 2006.
15. Hanft A, Eggleston CF, Bourgeois JA: Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 14:481-487, 2004. (Pubitemid 39473136)
16. Leibold J, Patel V, Hasan RA: Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 26: 1105-1108, 2004. (Pubitemid 39141813)
17. Mané A, Baeza I, Morer A, Lázaro ML, Bernardo M: Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia. J Child Adolesc Psychopharmacol 15:844-845, 2005. (Pubitemid 43042976)
18. Palakurthi HB, Parvin MM, Kaplan S: Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 30:47-51, 2007. (Pubitemid 46204318)
19. Rais AR, Kimmel S, Shrestha N, Rais TB, Coffey BJ: Atypical neuroleptic malignant syndrome in an adolescent. J Child Adolesc Psychopharmacol 18:215-220, 2008. (Pubitemid 351591444)
20. Robb AS, Chang W, Lee HK, Cook MS: Case study. Risperidone-induced neuroleptic malignant syndrome in an adolescent. J Child Adolesc Psychopharmacol 10:327-330, 2000. (Pubitemid 32103909)
21. Sharma R, Trappler B, N symptoms, and all treatments, interventions, and outcomes. syndrome. Ann Pharmacother 30:775-778, 1996.
22. Silva R.R, Munoz DM, Alpert M, Perlmutter IR, Diaz J: Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:187-194, 1999. (Pubitemid 29061935)
23. Skarpathiotakis M, Westreich N: NMS after clozapine initiation. J Am Acad Child Adolesc Psychiatry 44:1101-1102, 2005.
24. Spalding S, Alessi NE, Radwan K: Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 43:1457-1458, 2004. (Pubitemid 40468618)
25. Steingard R, Khan A, Gonzalez A, Herzog D: Neuroleptic malignant syndrome: Review of experience with children and adolescents. J Child Adolescent Psychopharmacol 2:183-198, 1992.
26. Strawn JR, Keck PE Jr: Early bicarbonate loading and dantroline for ziprasidone/haloperidol-induced neuroleptic malignant syndrome. J Clin Psychiatry 67:677, 2006. (Pubitemid 43764250)
27. Strawn JR, Adler CM, Strakowski SM, DelBello MP: Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine. J Child Adolesc Psychopharmacol 18:116-118, 2008.
28. Ty EB, Rothner AD: Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 16:157-163, 2001. (Pubitemid 32433233)
29. Zalsman G, Lewis R, Konas S, Loebstein O, Goldberg P, Burguillo F, Nahshoni E,Munitz H: Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health 16:179, 2004. (Pubitemid 38961304)
30. Zito et al.: Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatrics Adolesc Med 157:17-25, 2003.